Gilde Healthcare Services invests in nursing homes - Gilde Healthcare

Gilde Healthcare Services invests in nursing homes

25. Oktober 2010

Utrecht, The Netherlands – Gilde Healthcare Services (Gilde), a growth capital fund specialised in Healthcare Services, has acquired a significant minority stake in elderly care provider Stepping Stones Home & Care (Stepping Stones) of the Netherlands to fund further growth of the company.

Stepping Stones operates a chain of nursing homes providing care for elderly with Alzheimer’s disease and related conditions that need continuous support. The nursing homes offer a safe, protected and continuous care environment with affordable services tailored to the needs of residents (www.steppingstonesbv.nl).

Stepping Stones founding managers Arthur Scherpenzeel and Christiaan Sap commented:

“We are thrilled with the investment from Gilde. This investment not only enables us to expand the number of locations but we will also benefit from Gilde’s hands-on approach and healthcare expertise.

Jasper van Gorp, Partner of the Gilde Healthcare Services fund said:

“We were impressed by Stepping Stones’ ability to provide a very high quality yet affordable care home service. We believe that there is a considerable need for this type of service which can co-exist alongside care provided by the public sector in the Netherlands. This investment is aligned perfectly with our investment focus on high growth healthcare services companies.

GILDE HEALTHCARE COMPANY SYNEXA LIFE SCIENCES ACQUIRES ALDERLEY ANALYTICAL TO EXPAND BIOANALYSIS CAPABILITIES IN DRUG DEVELOPMENT

Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, announces the acquisition of Alderley Analytical Ltd, based in Manchester, UK. The transaction marks an important milestone in Synexa’s ‘buy and build’ growth strategy, underpinning...
3. Oktober 2024

Gilde Healthcare company Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer

Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug (ADC) conjugate program for solid tumors into the clinic in 2025 Founding CEO Marc Robillard, Ph.D., will...
1. Oktober 2024

Gilde Healthcare company Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer

Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug (ADC) conjugate program for solid tumors into the clinic in 2025 Founding CEO Marc Robillard, Ph.D., will...
1. Oktober 2024